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Abstract
Celiac disease (CD) is an immune-mediated systemic disorder elicited by gluten and 
related prolamins in genetically susceptible individuals, characterized by the presence of a 
variable combination of gluten-dependent clinical manifestations, CD-specific antibodies, 
HLA-DQ2 and HLA-DQ8 haplotypes, and enteropathy. Hepatitis B virus (HBV) infection 
is an important global public health problem that can cause chronic liver disease, and it is 
associated to a high risk of death from cirrhosis and hepatocellular carcinoma. Since 1982, a 
safe and effective HBV vaccine has been available, and recommendation for HBV vaccina-
tion has been extended to all infants to achieve protection against HBV infection. HBV vac-
cination is highly effective in eliciting a sustained immune response in immune-competent 
individuals. However, research papers have suggested that celiac patients may have low 
rate of protective antibodies after HBV vaccination. The failure of CD subjects to respond 
to HBV vaccination has great importance for public health policies as the nonresponders 
could be regarded as a reservoir for HBV. The aim of our work is to revise and to discuss 
the scarce literature on this field in order to provide clinical practice guidelines to establish 
the best surveillance program of response to HBV vaccine in CD pediatric patient.
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1. Introduction
Celiac disease (CD) is an immune-mediated systemic disorder elicited by gluten and related 
prolamins in genetically susceptible individuals, characterized by the presence of a variable 
combination of gluten-dependent clinical manifestations, CD-specific antibodies, HLA-DQ2 
and HLA-DQ8 haplotypes, and enteropathy. Genetic, immunological, and environmental 
factors therefore appear to be responsible for the disease. HLA-DQ2 is present in 90%–95% 
of patients with CD, whereas 5% carry the HLA-DQ8 haplotype and the remaining 5% at 
least one of the two DQ2 alleles [1, 2]. The prevalence of CD is high in the European and 
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North American population (1%), reaching 10%–15% in patients who have first-degree rela-
tives with this disease [1, 2].
HLA system has a fundamental role in identifying the antigens inoculated with the vaccines 
and in the production of specific antibodies [3, 4], and some HLA phenotypes seem to be pre-
dictive of a less effective immunological response [5].
In particular, the immunogenic peptides in the hepatitis B (HBV) vaccine determine the pro-
tective immune response to the virus through the HLA-DR and DQ molecules [6, 7], with the 
DR3-DQ2 and DR7-DQ2 haplotypes generally having a lower response rate [7–10].
HBV infection is one of the major causes of chronic liver disease, associated with a high risk 
of death from cirrhosis and hepatocellular carcinoma, and therefore represents an important 
global public health problem [11, 12]. To prevent it, since 1982, a safe and effective hepatitis 
B vaccine has been available. The one currently in use is a recombinant vaccine that contains 
HBV surface antigen (HBsAg) and causes the production of specific antibodies (anti-HBs) that 
protect against the infection [13]. Many epidemiologic studies have been conducted to deter-
mine the efficacy of the vaccine. A positive immune response to the vaccine is defined as the 
development of HBV anti-HBs at a titer of >10 mIU/mL, after a complete and appropriate 
immunization schedule, measured preferably 1–3 months after the last vaccine administration 
[14, 15]. The optimum response, conferring seroprotection against HBV infection, is defined as 
an anti-HBs titer ≥100 IU/l [14, 15]. Subjects that develop an anti-HBs titer between 10 and 100 
IU/ml are referred to as “poor responders.” Vaccinated subjects with an anti-HBs titer <10 mIU/
ml after completion of primary vaccine series are called “nonresponders” [16]. HBV vaccina-
tion is very effective, showing a sustained immune response in immune-competent individu-
als: the antibody response has been found to occur in more than 90% of the healthy subjects 
vaccinated with the standard dose regimen of 20 μg HBV vaccine given at 0, 1, and 6 months of 
intervals [17, 18]. However, among healthy immunocompetent subjects, approximately 4–10% 
do not produce protective levels of anti-HBs after immunization [19] depending on age, male 
gender, obesity, inappropriate vaccine storage conditions, route of administration, smoking, 
drug abuse, state of immunosuppression, and presence of specific HLA haplotypes.
2. Responses to vaccinations in celiac children
Data concerning antibody response of patients with CD to vaccine are scanty. Most studies in 
this field are addressed to HBV vaccination response, while fewer works are available about 
the immunological response to other vaccinations.
Several research papers have suggested that celiac patients may have low rate of protective 
antibodies after vaccinations such as HBV. The failure of CD subjects to respond to HBV vacci-
nation has great importance for public health policies as the nonresponders could be regarded 
as a reservoir for HBV [20]. The studies that have addressed the relation between CD and HBV 
vaccination in children are summarized in Table 1 [21–29]. In the earliest report involving 26 
celiac patients aged 9.2 ± 4.6 years and 18 age-matched controls, receiving the full comple-
ment of childhood vaccination (HBV, tetanus, rubella, Haemophilus influenzae type b), Park et al. 
[21] demonstrated that a significantly higher proportion of subjects in the CD group failed to 
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respond to HBV vaccine compared with controls (53.9% versus 11.1%; p < 0.05). However, all 
subjects in both groups tested positive for other vaccinations. These results led the authors 
to support the role of HLA haplotypes in response to HBV vaccine. Nemes et al. [22] evalu-
ated HBV vaccine response in CD patients in relation to disease activity and examined the 
possible role of dietary gluten in the failure to achieve protective antibody titers. The authors 
studied 128 biopsy-proven CD children and adolescents and 113 age-matched control sub-
jects; 22 patients with CD were prospectively vaccinated with a recombinant HBV vaccine after 
the diagnosis of CD during dietary treatment, while 106 CD patients received a recombinant 
HBV vaccine unrelated to CD diagnosis and dietary compliance. They found that a serocon-
version rate for anti-HBs was 95.5% (95% CI: 78.25–99.2%) after vaccination in the patients 
prospectively immunized, while the response rate was 50.9% and correlates with gluten intake 
(untreated patients 25.9%, non-strict diet 44.4%, strict diet 61.4%) when HBV immunization 
was performed unrelated to diagnosis and diet status suggesting that disease activity may play 
a primary role in vaccination failure rather than specific HLA alleles [22]. Subsequently, Ertem 
et al., to assess the response to HBV vaccine prospectively in a group of CD children and to 
explore the potential link between CD and HBV vaccine nonresponse, evaluated serologically 
for anti-HBs status 63 previously biopsy-proven CD patients on a strict gluten-free diet (GFD) 
and 54 healthy children. CD children who were anti-HBs negative at baseline were fully vac-
cinated prospectively and reevaluated for the response to HBV vaccine. The authors found that 
the response rate to HBV vaccine in CD patients prospectively vaccinated was 96.9%, which 
was as high as the response rate obtained in healthy population, and they concluded that treat-
ment with GFD and compliance to the treatment rather than the specific HLA alleles may 
improve the immune response to HBV vaccine in CD patients [23]. Balamtekin et al. conducted 
a study to compare the response rates to HBV vaccination in the first year of life, using two 
different immunization protocols. The total study group included 64 CD children (group 1 
who received HBV vaccination at birth, 2 and 9–12 months of life, and group 2 at birth, 1 and 
6 months of life) and 49 healthy controls. The authors found that the response rate to HBV 
vaccine and anti-HBs titers in CD patients who completed the HBV vaccination before 1 year 
of age were significantly lower compared to healthy controls, whereas no statistically signifi-
cant difference was observed with the two different HBV vaccination schedules [24]. Ertekin 
et al. compared the response to HBV vaccine between children with CD and healthy children 
and investigated the relationship between the patients’ responses to HBV vaccine, the clinical 
presentation of CD, and the dietary compliance in the patients. They evaluated the production 
of specific anti-HB surface antigen (HBsAg) in 52 CD patients and 20 age- and sex-matched 
healthy children who received HBV vaccination according to the standard immunization 
schedule. The authors found that anti-HBs titers of CD patients were positive in 32 (61%) and 
negative in 20 (38.5%) patients, while 18 (90%) of control subjects had positive anti-HBs titers. 
They found also statistically significant differences between negative anti-HBs titers, clinical 
presentation of CD, and dietary compliance in patients with CD (P < 0.05). Therefore, they con-
cluded that, in children with CD, the immune response to HBV vaccination may be improved 
by compliance to the GFD [25]. Leonardi et al. [26] in a retrospective report confirmed that CD 
patients have a lower percentage of response to HBV vaccination than healthy subjects. In fact, 
they found that 30 (50%) of 60 CD patients were nonresponders to HBV vaccination, compared 
to 7 (11.6%) of 60 controls. The same authors also found that a significantly higher number 
of nonresponders in adolescent patients older than 14 years and concluded that a very early 
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diagnosis of CD seems to increase significantly the percentage of responders suggesting that 
a short time of gluten introduction seems to play a favorable effect on the antibody memory 
[26]. Leonardi et al. [27] in a subsequent retrospective study, including 66 CD patients and 50 
healthy children, analyzed and compared the immunologic response against obligatory vac-
cination (HBV, diphtheria and tetanus component, and Bordetella pertussis) and against recom-
mended vaccination (Measles virus, Paramyxoviridae, and Rubella virus) in the two groups. The 
authors found similar response to obligatory and recommended vaccines into the two groups, 
except for HBV vaccine. Moreover, they compared patients whose diagnosis was made before 
or after 18 months of age and found that an early or a delayed diagnosis does not significantly 
modify the immunological response, except for that one involved in the HBV vaccination. 
Thus, the immunologic response did not seem to be influenced by the natural history of CD 
[27]. Urganci and Kalyoncu determined the rate of response to hepatitis A (HBA) and HBV 
vaccine, the duration of protection against HAV and HBV, and the incidence of acute HAV or 
HBV infections during follow-up in 30 pediatric patients with CD and compared them with 
50 healthy age-, sex-, and body mass index-matched controls [28]. They found that 14 (46%) 
of 30 CD patients and 15 (30%) of the controls had natural immunity for HAV, whereas all 
patients and controls did not show evidence of earlier exposure to HBV. Sixteen patients and 
35 controls received HAV vaccine, and HBV vaccine was administered to all CD patients and 
controls; protective anti-HAV antibodies were developed in 12 (75%) of the patients and all the 
controls (75% versus 100%, respectively). Thirty patients and 50 controls received HBV vac-
cine, and 70% of the patients versus 90% of the controls achieved seroprotection. The authors 
concluded that the rate of seroconversion to the HBV and HAV vaccine is lower in CD patients 
than in healthy controls. Finally, in a very recent paper, Leonardi et al. comparing a group of 
patient affected by diabetes mellitus type 1 (DMT1) and CD and a group affected by DMT1 
without CD (both groups had similar HLA haplotype) found a higher nonsignificant percent-
age of nonresponders in DMT1/CD group than in DMT1 (53.3% versus 38.2%); comparing the 
DMT1/CD group with CD group, the authors found a similar percentage (53.3% versus 50%) 
of nonresponders, and this result indirectly confirmed that gluten can favor a further decrease 
of efficacy to HBV vaccine, beyond the HLA system [29].
Author/
references
Year Country Study design Patient population 
and sample size
Vaccine (%) of 
nonresponders
HLA
Park et al. 
[21]
2007 Japan Prospective 26 (mean age 9.2 ± 4.6 
years) untreated CD 
vs 18 (mean age 10.4 ± 
3.8) controls
HBV 53.9% vs 11.1%; 
P < 0.05
NA
Nemes 
et al. [22]
2008 Finland Prospective 22 (mean age 8.8 
years) treated 
CD prospectively 
immunized; 27 
(mean age 16.7 years) 
untreated CD; 79 
(mean age 16.7 years) 
treated CD
vs
113 (mean age 16.1 
years) controls
HBV 0.5%
74.0%
38.6%
vs
24.8%; P < 0.001, 
P < 0.001, P = 
0.102
Group 1 (22 
treated CD): 
HLA DQ2
Group 2 (53/106 
treated and 
untreated CD):
51: HLA DQ2
2: HLA DQ8
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3. Pathogenetic role of HLA system in vaccination unresponsiveness in 
celiac disease
The mechanism for hepatitis B vaccination failure in patients with CD is not clear. A few 
hypotheses have been proposed. Multiple candidate genes influence the ability to respond 
Author/
references
Year Country Study design Patient population 
and sample size
Vaccine (%) of 
nonresponders
HLA
Leonardi  
et al. [26]
2009 Italy Retrospective 60 (mean age 9.32 
years) treated CD vs
60 (mean age 10.1 
years) controls
HBV 50% vs 11.6%; P 
< 0.0001
15/60: 13 
HLA-DQ2
2 HLA-DQ8
Ertem et al. 
[23]
2010 Turkey Retrospective
Prospective
40 vaccinated (mean 
age 12.4 ± 5.4 years) 
treated CD vs
54 (mean age 9.8 ± 3.6 
years) controls
28 prospectively 
vaccinated treated CD
HBV 32.5% vs 14.8%; 
P < 0.05
3.6%
37.5% CD
23.8% controls: 
HLA DRB1*03
21% CD
2.4% controls: 
HLA DRB1*07
55% CD
14.6% controls: 
HLA DQB1*02
30% CD
47.6% controls: 
HLA DQB1*03
Ertekin  
et al. [25]
2011 Turkey Retrospective 52 (mean age 10.7 ± 4 
years) CD vs 20 (mean 
age 10.7 ± 4 years) 
controls
HBV 38.5% vs 10%; P 
< 0.05
NA
Balamtekin 
et al.[24]
2011 Turkey Retrospective 64 (mean age 4.69 ± 
2.31 years) treated 
and untreated CD vs 
49 (mean age 5.45 ± 
2.92 years) controls
HBV 21.9% vs 4.1%; P 
= 0.001
NA
Urganci 
and 
Kalyoncu 
[28]
2013 Turkey Prospective 30 (mean age 6.15 
± 4.1 years) treated 
and untreated CD vs 
50 (8.13 ± 1.7 years) 
controls
HBV 30% vs 10%; P 
= 0.03
NA
Leonardi  
et al. [27]
2011 Italy Retrospective 66 (mean age 8.34 ± 
3.47 years) CD vs 50 
(mean age 7.58 ± 3.51 
years) controls
HBV 53% vs 16%; P < 
0.0001
NA
Leonardi  
et al. [29]
2015 Italy Prospective 30 (mean age 6 years) 
CD/DMT1 vs 100 
(mean age 13.6 years) 
DMT1 vs 60 (mean 
age 8.6 years) CD
HBV 53.3% vs 38.2% 
vs 50%; P > 0.02
NA
HBV hepatitis B virus; CD celiac disease; HLA human leukocyte antigen; NA nonavailable; DMT1 diabetes mellitus type 1.
Table 1. Response to HBV vaccination in CD children and adolescents compared to healthy subjects.
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to the recombinant HBV vaccine [9, 30–32]. HLA is believed to contribute significantly to the 
genetic susceptibility immune response variations to the vaccine [33]. Poor or nonresponsive-
ness to HBV vaccine has been associated with HLA-DQ2, DR3, and DR7 alleles, which are 
also associated with CD [9, 10, 34]. In particular, HLA genotype DQ2, found in 90–95% of 
celiac patients, may have a fundamental role in the predisposition to a weaker immunization 
to recombinant hepatitis B vaccine in these patients. The HLA is coded by the major histocom-
patibility complex (MHC) group of genes located on chromosome 6 in the human genome, 
and they are essential for determining the specificity of an individual’s immune response [35]. 
There are three classes of HLA: HLA class I, HLA class II, and HLA class III. Among them, 
HLA class II molecules have the task of presenting antigens to the T lymphocytes from out-
side the cell. Antibody-producing B cells are then stimulated to produce specific antibodies 
by these antigens [36]. HLA-DQ2 haplotype would be responsible for the failure of induction 
of the Th2 response needed to promote the differentiation of B cells and the formation of 
memory B cells necessary for immunization.
Defective or insufficient HBsAg-specific T-helper cells, inadequate T-helper 1, and T-helper 
2 cytokine production [37–39], or diminished expression of cell contact signal between acti-
vated T and B cells, like CD40L [40] may also be responsible for the lack of response to 
HBsAg [41, 42]. On this regard, interleukin genotypes (IL10, IL12, IL18) were associated 
with the anti-HBs antibody development in response to HBsAg in hemodialysis patients [43, 
44]. Chen et al. in 2011 found that serum anti-HBsAg response to HBV vaccine in healthy 
population was closely related to four specific single-nucleotide polymorphism (SNPs) in 
the IL4, IL4RA, IL13, and Toll-like receptor (TLR2) genes and suggested that variation in 
these structures may influence the duration and intensity of HBV vaccine-induced immune 
response [45].
Other studies suggested that compliance with a GFD is responsible for the response to the 
hepatitis B vaccine in patients with CD. Several studies have hypothesized gluten intake as a 
cause of failed immunity upon vaccination. Gluten may be implicated because both HBsAg 
protein fragments and gliadin peptides bind to HLA-DQ2 molecules and induce proliferation 
of T lymphocytes. Defective antibody production may result from competition between the 
proteins [22, 23].
4. New approaches in hepatitis B vaccination in celiac children
Inadequate response to HBV immunization in CD patients represent a public health con-
cern because the group of nonresponder patients could act as an HBV infection reservoir. For 
this reason, response to HBV vaccine should be investigated in children with CD. To protect 
this population and to achieve the goal of universal protection, new immunization strategies 
were proposed for CD: the first one is the use of booster and/or higher doses of HBV vaccine 
by intramuscular (IM) route, and the second one addresses on the use of intradermal route 
(ID). The studies that have addressed new immunization strategies in CD are summarized in 
Table 2 [22, 23, 46, 47].
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Author/references Year Country Study design Patient 
population and 
sample size
VAC Ag Type of 
vaccine
Route Number of 
booster doses
% Seroconversion
Nemes et al. [22] 2008 Finland Prospective 37 (mean age 
16.7 years) 
nonresponders CD 
on GFD
HBV Recombinant IM 1 97.3%
Ertem et al. [23] 2010 Turkey Prospective 28 (12.4 ± 5.4 years) 
nonresponders CD
HBV Recombinant IM Three doses of 
HBV vaccine
96.4%
Leonardi et al. [46] 2010 Italy Prospective 20 nonresponders 
CD to IM 
vaccination
HBV Recombinant ID 4 90%
Leonardi et al. [47] 2012 Italy Prospective
Randomized
58 (mean age 
9.8 ± 6.2 years) 
nonresponders CD
HBV Recombinant 30 ID vs 28 IM 3 After first dose: 
ID:76.7% vs
IM: 78.6%
After third dose:
ID: 90% vs IM: 
96.4%
High responders 
(anti-HBs >1000 
IU/l):
ID: 40%
IM: 7%; P < 0.01
CD celiac disease; IM intramuscular; ID intradermal; VAC vaccine; Ag antigen; GFD gluten-free diet; HBV hepatitis B virus; anti-HBs anti-hepatitis B surface
Table 2. Seroconversion rate in CD children and adolescents after IM or ID HBV vaccination.
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Nemes et al. administered intramuscularly to 37 nonresponder CD children on GFD, the 
booster dose of 20 μg of recombinant HBV vaccine, and found that 36 out 37 (97.3%) showed 
seroconversion 4 weeks after vaccination. However, success with the booster vaccination after 
controlled GFD suggests that disease activity may play a primary role in vaccination failure 
[22]. Few studies that exist about HBV vaccine administered by ID route in CD patients unre-
sponsive to IM recombinant vaccine. Leonardi et al. revaccinated 20 CD children and adoles-
cents with a 2 μg dose of recombinant intradermal HBV vaccine. After 4 weeks they found 
that 15 out 20 patients (75%) showed a protective titer of anti-HBs [22, 23].
Subsequently, Leonardi et al. conducted a prospective, randomized study on 58 CD patients, 
vaccinated in the first year of life, without protective HBV antibodies as demonstrated by 
blood analysis. They performed in all patients randomly an HBV vaccination booster dose by 
ID or IM route. In 30 CD children, a 2 μg dose of recombinant HBV vaccine was administered 
by the ID route, while 28 CD patients received by IM route 10 μg dose of the same vaccine. 
Four weeks after every booster dose, 90% of ID patients and 96.4% of IM subjects showed a 
protective anti-HBs titer after a third booster dose. The authors concluded that both routes are 
effective in revaccinating CD patients; however, the ID route seems to produce a significantly 
higher percentage of higher responders [47].
Data suggest that the ID route offers greater immunogenicity due to direct delivery of antigen 
to the skin immune system, using even lower doses of antigen than IM route [47]. Moreover, 
the presence of a skin reaction on the site of the intradermal injection could represent a less 
expensive strategy to test serum anti-HBs response after the booster dose [48]. Economic stud-
ies suggest that the substantial cost-saving benefits could be achieved using a fraction of the 
IM dose via an ID route [48, 49].
5. Conclusions
The available literature shows that HBV vaccine response is lower in celiac subjects compared 
with healthy ones. Some authors hypothesize that the failure to respond to HBV vaccination is 
related to specific HLA association, whereas others argue that exposure to gluten at the time 
of vaccination may play an important role in unresponsiveness to the HBV vaccine. Therefore, 
nonresponsiveness to the HBV vaccination in CD patients represents a serious public health 
problem because of the large diffusion of CD that affects about 1% of the European popula-
tion. Consequently, new vaccination strategies have been proposed to achieve full protection 
in this context, including the administration of booster doses of HBV vaccine by the intramus-
cular or the intradermal route. An evaluation of the response to HBV vaccine should be con-
sidered as a routine assessment in children newly diagnosed with CD who were previously 
vaccinated for HBV. Whenever unresponsiveness occurs, certain measures must be taken into 
account, such as revaccination utilizing ID route, which offers a potentially greater immuno-
genicity than the IM one, even using lower doses, due to the direct delivery of antigen to the 
skin immune system. Moreover, the revaccination should be done after the decrease of specific 
antibodies, which usually occurs after about 1 year of GFD, seen as some studies support GFD 
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as crucial to vaccine responsiveness. More randomized controlled studies with a prospective 
design are needed for CD patients in order to clarify this topic.
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